Syed Alam, MD
Pulmonary Disease · Bakersfield, CANPI 1073541512
Payments from drug & device makers
Across 686 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$943
- Actelion Pharmaceuticals US, Inc.$827
- Philips North America LLC$439
- Novo Nordisk$378
- plus $5K from 53 others
What the payments were for
- Food & beverage$12,37997%
- Education$3663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$136
- BREZTRI$136
- Pulmonx Endobronchial Valve EBV$113
How this compares
$12,745 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 154 | $1,933,969 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 506 | $384,226 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 27 | $368,033 |
| ZemairaAlpha-1-Proteinase Inhibitor | 19 | $149,676 |
| EliquisApixaban | 112 | $75,789 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 120 | $66,406 |
| JanuviaSitagliptin Phosphate | 71 | $60,545 |
| Breo ElliptaFluticasone/Vilanterol | 103 | $46,241 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 72 | $39,908 |
| Spiriva RespimatTiotropium Bromide | 59 | $37,127 |
| FarxigaDapagliflozin Propanediol | 37 | $36,949 |
| XareltoRivaroxaban | 45 | $35,265 |
| OzempicSemaglutide | 26 | $30,549 |
| JardianceEmpagliflozin | 38 | $29,779 |
| MounjaroTirzepatide | 31 | $28,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Jardiance, Combivent Respimat | $943 | $2,107,474437 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,920 | $490,999728 claims |
| Grifols USA, LLCProlastin C | $329 | $368,03327 claims |
| CSL BehringZemaira | $26 | $149,67619 claims |
| PfizerEliquis | $194 | $75,789112 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,984 | $74,162114 claims |
| MerckJanuvia, Janumet | $203 | $70,31289 claims |
| Novo NordiskOzempic, Rybelsus | $378 | $52,21143 claims |
| Johnson & JohnsonXarelto | $220 | $35,26545 claims |
| Lilly USA, LLCMounjaro | $66 | $28,92131 claims |
| AbbVieLinzess | $130 | $12,85523 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $26 | $4,78516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Bakersfield
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.